Servier

Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
Servier
3 Programs
n.d./n.d.
Bispecific
Immuno-Oncology U.S. for 1
bispecific
Discovery Phase in progress
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started